The objective of this study was to further investigate the potential utility of a set of specific microRNAs previously identified as biomarkers in MS [16,23] in a larger cohort of MS patients and to combine these data with the more studied and validated serum NfL (sNfL). The gene discussed is NEFL; the disease is myeloid sarcoma.